Status:
UNKNOWN
Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia
Lead Sponsor:
Hospital General de Mexico
Conditions:
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
10-21 years
Phase:
NA
Brief Summary
Acute lymphoblastic leukemia, is the most frequent cancer in children and adolescents. Some genes have been described to produce drug resistance, as ABCB1 probably by lack of activation of AMPK. Some ...
Detailed Description
Acute lymphoblastic leukemia, is the most frequent cancer in children and adolescents. By now, chemotherapy agent combination achieves remission in more than 90% of patients. But, adolescents have an ...
Eligibility Criteria
Inclusion
- Newly diagnosed adolescents with acute lymphoblastic leukemia by morphology analysis in bine marrow
- Adolescents between 10 and 21 years old
- Participants with the informed consent signed by themselves and the parents or legally authorized representative.
Exclusion
- Participants with previous use of any antineoplastic drug
- Down syndrome patients
Key Trial Info
Start Date :
February 9 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05326984
Start Date
February 9 2021
End Date
December 1 2023
Last Update
April 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital General de México
Mexico City, Mexico, 06720